Head to head
BPC-157 vs Larazotide
Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.
Verdict
Not an either/or
What you are actually choosing between
Before anything else: the dataset lists BPC-157 and Larazotide in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.
Both are classed here as healing and repair compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is gut health and inflammation. On this site's goal weighting — an editorial priority score, not a measure of effect size — BPC-157 rates 5/5 for gut health and Larazotide rates 5/5. Outside that overlap only BPC-157 goes further, carrying weight for injury repair and joint and tendon health; Larazotide's declared goals stop at the overlap.
The evidence
Larazotide sits one step firmer: controlled human trials behind it, without an approval — its phase 3 was stopped for futility at interim analysis. BPC-157 has some human data, but it is small, old, or uncontrolled — the animal data is extensive; the human trial data is not. One tier is a real difference but not a decisive one; it should not on its own settle the choice.
How they differ in practice
BPC-157 is a subcutaneous injection and taken by mouth; Larazotide is taken by mouth. Neither one forces you onto a needle.
BPC-157 has a characterized half-life of 4 h; Larazotide does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.
Committed time differs: BPC-157 runs 8 weeks, Larazotide runs 12 weeks.
Risk and difficulty
The contraindication lists are not the same: BPC-157 flags active malignancy, which Larazotide does not; Larazotide flags under 18, which BPC-157 does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.
BPC-157 is rated beginner here and Larazotide intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
BPC-157
Extensive animal data on tendon, ligament and gut healing. Human trial data is limited and it is not an approved medicine in the US.
Larazotide
A zonulin antagonist taken orally as a capsule; it acts locally in the gut lumen and is essentially not absorbed systemically. It has run randomized placebo-controlled trials in coeliac disease, including a phase 3 that was stopped for futility at interim analysis. Trial dosing was 0.5 mg three times daily before meals, with 1 mg and 2 mg arms performing no better than 0.5 mg. This app has no three-times-daily option, so the schedule below is an approximation of the studied regimen. Not an approved medicine.
Side by side
The numbers
| Attribute | BPC-157 | Larazotide |
|---|---|---|
| Class | Healing & repair | Healing & repair |
| Routes | Subcutaneous, Oral | Oral |
| Dose range | 200 mcg–500 mcg (typical 250 mcg) | 500 mcg–2 mg (typical 500 mcg) |
| Frequency | Once daily | Three times daily |
| Half-life | 4 h | Not characterized |
| Cycle length | 8 weeks | 12 weeks |
| Experience | Beginner | Intermediate |
| Evidence | Limited human data | Controlled human trials |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: BPC-157
Goals
Where they overlap, and where they do not
| Goal | BPC-157 | Larazotide |
|---|---|---|
| gut health | BPC-157: 5/5 | Larazotide: 5/5 |
| inflammation | BPC-157: 4/5 | Larazotide: 3/5 |
| injury repairone only | BPC-157: 5/5 | Larazotide: — |
| joint and tendon healthone only | BPC-157: 4/5 | Larazotide: — |
| immune supportone only | BPC-157: — | Larazotide: 2/5 |
| recovery and sleepone only | BPC-157: 2/5 | Larazotide: — |
They overlap on 2 goals and diverge on 4. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.